No Data
No Data
Kubota Pharmaceutical HD---1Q strengthens preparations for Kubota Glass sales expansion and product improvement/service creation
Kubota Pharmaceutical Holdings <4596> announced consolidated financial results (IFRS) for the 1st quarter (January to March 24) of the fiscal year ending 2024/12 on the 14th. Business revenue decreased 2.8% from the same period last year to 0.05 billion yen, operating loss was 337 million yen (loss of 445 million yen in the same period last year), loss before income tax was 343 million yen (loss of 444 million yen), and quarterly losses attributable to owners of parent companies were 343 million yen (loss of 444 million yen). Wearable myopia device in medical devices
KUBOTA PHARMACEUTICAL HLDGS: Confirmation Letter
KUBOTA PHARMACEUTICAL HLDGS: Quarterly Report - 10th Term 1st Quarter (2024/01/01 - 2024/03/31)
KUBOTA PHARMACEUTICAL HLDGS: Summary of Financial Results for the 1st Quarter of the Fiscal Year Ending December 2024/12 [IFRS] (Consolidated)
Kubota Pharmaceutical HD --- New Patent Acquired in US
Kubota Pharmaceutical Holdings <4596> announced on the 9th that its subsidiary Kubota Vision Ink (Washington, USA) has obtained a new patent in the United States. Acquired patents relating to the at-home/remote ophthalmology medical retinal monitoring device (Patient Based Ophthalmology Suite) “eyeMO” and Kubota glasses technology. The name of the first invention is SYSTEM AND METHOD FOR OPTICAL COHER
Emerging Market Stock Digest: Matsuya R&D continues to increase drastically, and Metalial continues to increase drastically for 5 days
Significant continuous growth. The operating profit forecast for the fiscal year ending 24/3 has been revised upward from the previous 1200 billion yen to 1,270 billion yen (previous fiscal year results 611 million yen).
No Data